Segall Bryant & Hamill LLC Makes New $715,000 Investment in Innoviva, Inc. (NASDAQ:INVA)

Segall Bryant & Hamill LLC acquired a new position in shares of Innoviva, Inc. (NASDAQ:INVA - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 37,039 shares of the biotechnology company's stock, valued at approximately $715,000. Segall Bryant & Hamill LLC owned 0.06% of Innoviva as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. US Bancorp DE boosted its stake in Innoviva by 24.5% during the 3rd quarter. US Bancorp DE now owns 2,875 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 566 shares during the last quarter. GAMMA Investing LLC boosted its position in Innoviva by 18.5% during the third quarter. GAMMA Investing LLC now owns 4,119 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 643 shares during the last quarter. ProShare Advisors LLC grew its stake in Innoviva by 6.2% during the 1st quarter. ProShare Advisors LLC now owns 16,150 shares of the biotechnology company's stock valued at $246,000 after acquiring an additional 942 shares in the last quarter. SummerHaven Investment Management LLC raised its holdings in Innoviva by 1.7% in the 2nd quarter. SummerHaven Investment Management LLC now owns 59,853 shares of the biotechnology company's stock valued at $982,000 after acquiring an additional 980 shares during the last quarter. Finally, Evergreen Capital Management LLC lifted its stake in Innoviva by 10.9% in the 2nd quarter. Evergreen Capital Management LLC now owns 12,321 shares of the biotechnology company's stock worth $202,000 after purchasing an additional 1,209 shares in the last quarter. 99.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on INVA. Cantor Fitzgerald restated an "overweight" rating on shares of Innoviva in a research report on Tuesday, July 30th. StockNews.com lowered shares of Innoviva from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, August 6th.

Innoviva Stock Performance

Shares of INVA traded up $0.04 during mid-day trading on Monday, reaching $19.19. 926,006 shares of the company's stock were exchanged, compared to its average volume of 591,316. The business's fifty day simple moving average is $19.60 and its 200-day simple moving average is $18.12. The stock has a market capitalization of $1.20 billion, a PE ratio of 27.81 and a beta of 0.57. Innoviva, Inc. has a 52-week low of $13.60 and a 52-week high of $21.28. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.79 and a quick ratio of 1.64.

Innoviva (NASDAQ:INVA - Get Free Report) last announced its earnings results on Wednesday, November 6th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.27 by ($0.25). The business had revenue of $89.51 million for the quarter. Innoviva had a return on equity of 20.84% and a net margin of 18.31%. On average, equities research analysts expect that Innoviva, Inc. will post 0.33 earnings per share for the current year.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.